Physician profile
Heather Ditto
NPI 1346736717
$2,121.07
in general payments reported to CMS, 2019-2025
20 companies · $1,868 in 2025
The $1,868 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $36.26 · 2024: $39.80 · 2025: $1,868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,907.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $503.30 | 2025 | Nucala, Trelegy Ellipta |
| Insmed, INC. | $256.87 | 2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $223.88 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $223.44 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $207.92 | 2025 | Tezspire, Airsupra |
| Astellas Pharma US INC | $134.41 | 2021 | |
| Merck Sharp & Dohme LLC | $95.63 | 2022-2025 | Winrevair, Verquvo |
| Alnylam Pharmaceuticals INC. | $90.45 | 2024-2025 | Onpattro, Amvuttra |
| Verona Pharma, INC. | $81.89 | 2025 | Ohtuvayre |
| Boston Scientific Corporation | $74.55 | 2022-2025 | Cds - Mct/Cem Monitoring |
| Viatris Specialty LLC | $41.75 | 2025 | Yupelri |
| Abbvie INC. | $29.95 | 2021 | |
| Vifor Pharma, INC. | $26.93 | 2025 | Zemaira |
| Grifols USA, LLC | $22.63 | 2025 | Prolastin-C Liquid |
| Philips North America LLC | $22.13 | 2025 | Vest Therapy Und |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.99 | 2025 | Mounjaro |
| Paratek Pharmaceuticals, INC. | $19.32 | 2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.64 | 2025 | Jascayd |
| Takeda Pharmaceuticals U.S.A., INC. | $15.83 | 2025 | Glassia |
| Medtronic, INC. | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Ditto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.